There is much excitement in the U.S. bio market right now around NASH mergers/acquisitions, and we know Immuron is looking for a partner and, according to our CEO, multiple large pharmas sent them letters congratulating Immuron on the March 2018 NASH results. If we assume our CEO is being honest about the letters and their contents, and the fact that we just hired a U.S. based M&A specialist to our Board and received a 2nd U.S. NASH patent on our tech....seems like the stars are aligning.
IMC up over 20% in Last 30 Days, page-3
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
